Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02571634 · ClinicalTrials.gov registry record · Phase 4
Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints
A Phase 4 study of Minor Procedural Pain, sponsored by Defense and Veterans Center for Integrative Pain Management.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT02571634: Completed Phase 4 study of Minor Procedural Pain, sponsored by Defense and Veterans Center for Integrative Pain Management.
NCT02571634 is a Phase 4 study of Minor Procedural Pain that has completed, run by Defense and Veterans Center for Integrative Pain Management. The registered enrollment target is 23 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02571634, a Phase 4 study of Minor Procedural Pain, has completed, sponsored by Defense and Veterans Center for Integrative Pain Management.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness, feasibility and safety of intranasal fentanyl (Lazanda) as an alternative to the current gold standard (diazepam) to produce anxiolysis and improve patient comfort during and after radiofrequency ablations of the lumbar facet joints. If this pilot study shows a positive effect and Lazanda is found to be feasible and safe for use during procedures, future larger scale studies can be done.
Primary Outcome
Adverse events will be recorded by a yes or no as to their occurence
Conditions Studied
Interventions
- DRUG Lazanda
Study Locations (1)
North Carolina
- Womack Army Medical Center - Fort Bragg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 4 |
What the finished NCT02571634 record still lists
NCT02571634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Minor Procedural Pain appearing as the primary indexed condition, and to 1 intervention - of which Lazanda is the first listed.
NCT02571634 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02571634 about?
NCT02571634 is a clinical study titled "Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints". The purpose of this study is to evaluate the effectiveness, feasibility and safety of intranasal fentanyl (Lazanda) as an alternative to the current gold standard (diazepam) to produce anxiolysis and improve patient comfort during and after radiofrequency ablations of the lumbar facet joints. If thi...
What is the current status of trial NCT02571634?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2015-05. Estimated completion is 2016-01.
What conditions does trial NCT02571634 study?
This clinical trial studies the following conditions: Minor Procedural Pain.
What interventions are being tested in trial NCT02571634?
The interventions under investigation include: Lazanda (DRUG).
Who is sponsoring clinical trial NCT02571634?
This trial is sponsored by Defense and Veterans Center for Integrative Pain Management, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02571634 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02571634's enrollment target sits among peer trials
23 1725th of 2000 higher than 271 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia